BioCardia, Inc. (BCDAW) Comparison with companies in other sectors?

BioCardia, Inc. has a share price of 1.66M. You can analyze BioCardia, Inc. (BCDAW) competitors across different market sectors through stock heatmaps.

What are BCDAW's NET and operating margins?

BioCardia, Inc. (BCDAW) operating margin is around 104.11, and net profit margin is approximately 152.56 as of the latest reports.

In what way does BCDAW's earnings per share (EPS) trend reflect its financial momentum?

BioCardia, Inc. (BCDAW) EPS is -3.20 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BioCardia, Inc. is -0.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BioCardia, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BioCardia, Inc. like P/E which is -1.33, P/B which is -7.33, and PEG which is -0.06. Compare them with sector averages to evaluate if the stock is priced fairly.

BioCardia, Inc.

BCDAW•NASDAQ

Healthcare

Biotechnology

$0.006

$-0.00(-3.17%)

Fundamental Analysis of BioCardia, Inc. (BCDAW)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-3.20

P/E Ratio

-0.00

ROE

-307.93%

Net Margin

152.56%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$10.12K

Shares OutstandingTotal number of shares issued

$1.66M

Book Value/ShareNet worth per share

$-0.33

Revenue/ShareAnnual revenue per share

$-0.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-3.2

Net MarginNet income as percentage of revenue

15256.36%

Operating MarginOperating income as percentage of revenue

10410.91%

ROEReturn on shareholders' equity

-30792.66%

ROAReturn on total assets

-387.40%

ROCEReturn on capital employed

536.14%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.75

Cash/ShareCash and equivalents per share

$0.20

FCF YieldFree cash flow as percentage of market cap

-65.62%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BCDAWFinancial Ratios Analysis details for BCDAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BCDAWSector Benchmarking details for BCDAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BioCardia, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BioCardia, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BioCardia, Inc.'s unique business strengths and challenges.

Key Financial Metrics for BioCardia, Inc.

For BioCardia, Inc., essential financial indicators include EPS -3.20, PE -0.00, and ROE -307.93. These key ratios reveal insights into BioCardia, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare BioCardia, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BioCardia, Inc.

Metrics like Net Margin 15256.36% and ROA -387.40% shed light on how well BioCardia, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BioCardia, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of BioCardia, Inc.

Using ratios such as P/B Ratio -7.33 and PEG Ratio -0.06, investors can assess whether BioCardia, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with BioCardia, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BioCardia, Inc.

Financial health indicators, such as Debt/Equity Ratio -0.56 and Cash Flow $-1.75, provide a snapshot of BioCardia, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BioCardia, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BioCardia, Inc.

Investing in BioCardia, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BioCardia, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;